Omega Therapeutics Inc (OMGA) Peer Comparison

$0.05

$0.00 (7.78%)

As on 28-Apr-2025 09:30EDT

Market cap

$8 Mln

Revenue (TTM)

$8 Mln

P/E Ratio

--

P/B Ratio

0.2

Div. Yield

0 %

Edit

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Market cap ($ Mln)	8	78	2
Revenue ($ Mln)	8	--	2
Net Profit ($ Mln)	-73.09	-48.96	-34.58
Net Margin (%)	-902.93	--	-2,074.09
RoE (%)	-276.36	-62.96	-215.60
Price to Earnings	--	--	--
Price-To-Book	0.23	35.57	0.17

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Operating Revenue	8.10	0.00	1.67
Cost of Revenue	12.94	0.10	18.63
Gross Profit	-62.78	-0.10	-28.97
Operating Expenses	78.65	81.41	37.63
Operating Profit (EBIT)	-74.15	-81.41	-35.96
Other Income	0.00	--	0.00
Profit before Tax	-73.09	-75.47	-34.58
Provision for Tax	5.81	0.06	-27.28
Profit after Tax (Net Income)	-73.09	-75.52	-34.58
Minority Interest	0.00	--	0.00
Consolidated Profit	0.00	--	0.00

Liabilities ($ Mln)

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Shareholder's Funds	11.54	109.46	9.15
Minority Interest	0.00	--	0.00
Non-Current Liabilities	117.01	0.33	0.00
Current Liabilities	24.17	17.64	6.45
Total Liabilities	204.37	127.42	36.73

Assets ($ Mln)

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Non-Current Assets	113.77	3.19	0.15
Current Assets	38.95	124.23	15.45
Total Assets	204.37	127.42	36.73
Total Debt*	128.13	0.68	0.19
Net Current Assets	14.78	106.60	8.99

Cashflow ($ Mln)

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Cash From Operating Activities	-91.51	-56.78	-32.16
Cash Flow from Investing Activities	--	--	--
Cash from Financing Activities	41.82	46.00	1.07
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
ROCE (%)	-61.86	-63.47	61.76
ROE (%)	-276.36	-63.95	-215.60
ROA (%)	-34.68	-57.49	-98.22
EBIT Margin (%)	-703.19	--	-3,246.13
Net Margin (%)	-902.93	--	-2,074.09
Cash Profit Margin (%)	0.00	--	--

Growth Ratios

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Revenue Growth (%)	184.93	--	165.87
EBIT Growth (%)	48.43	--	-23.94
Net Profit Growth (%)	31.48	-46.61	16.08
EPS Growth (%)	--	--	17.49
Book Value Growth (%)	--	--	104.83

Valuation Ratios

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Price / Earnings	--	--	-0.04
Price / Book Value	--	--	0.05
Dividend Yield (%)	--	--	--
EV/EBITDA	-0.59	1.50	-14.47
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Debt to Equity	1.00	0.01	0.00
Short term debt to equity ratio	1.38	0.00	0.02
Current Ratio	1.61	7.04	2.39
Quick Ratio	1.61	--	2.39
Interest Coverage	-30.46	-30.40	-4,320.88

Operating Efficiency Ratios

	Omega Therapeutics Inc (OMGA)	Aerovate Therapeutics Inc (AVTE)	Oncternal Therapeutics (ONCT)
Debtors to sales (%)	6.00	--	20.64
Asset Turnover	0.04	0.00	0.05
Receivable days	518.48	--	188.44
Inventory Days	114.93	--	0.63
Payable days	13.11	9,456.55	24.95
Cash Conversion Cycle	620.31	--	164.12

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly